New combo aims to stop liver cancer recurrence in High-Risk patients

NCT ID NCT07337460

Recruiting now Disease control Sponsor: Northern Jiangsu People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a combination of Icaritin soft capsules and a liver-directed chemotherapy infusion (mFOLFOX) can prevent hepatocellular carcinoma from coming back after surgery in patients with high-risk features. About 30 participants will receive the treatment for up to a year. The study tracks how long patients stay cancer-free and their overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Icaritin soft capsules and mFOLFOX chemotherapy (oxaliplatin, leucovorin calcium, 5-fluorouracil)
What this could lead to: If it works, this combination could help prevent liver cancer from coming back after surgery in patients at high risk of recurrence.
What could go wrong: This is a small, early-phase trial with only 30 participants and no comparison group, so results may not be conclusive. The chemotherapy and Icaritin can cause side effects like nausea, fatigue, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Clinical Medical College of Yangzhou University
RECRUITING

Yangzhou, Jiangsu, 225001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.